UK Markets close in 5 hrs 5 mins
  • FTSE 100

    7,334.70
    -5.20 (-0.07%)
     
  • FTSE 250

    23,237.14
    -1.03 (-0.00%)
     
  • AIM

    1,201.59
    +1.54 (+0.13%)
     
  • GBP/EUR

    1.1694
    -0.0053 (-0.45%)
     
  • GBP/USD

    1.3198
    -0.0044 (-0.3286%)
     
  • BTC-GBP

    37,343.32
    -1,788.16 (-4.57%)
     
  • CMC Crypto 200

    1,282.36
    -159.40 (-11.06%)
     
  • S&P 500

    4,686.75
    +95.08 (+2.07%)
     
  • DOW

    35,719.43
    +492.43 (+1.40%)
     
  • CRUDE OIL

    71.19
    -0.86 (-1.19%)
     
  • GOLD FUTURES

    1,791.00
    +6.30 (+0.35%)
     
  • NIKKEI 225

    28,860.62
    +405.02 (+1.42%)
     
  • HANG SENG

    23,996.87
    +13.21 (+0.06%)
     
  • DAX

    15,703.26
    -110.68 (-0.70%)
     
  • CAC 40

    7,029.38
    -36.01 (-0.51%)
     

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

·3-min read

DGAP-News: Imcyse SA / Key word(s): Personnel
03.11.2021 / 13:00
The issuer is solely responsible for the content of this announcement.

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

Liège, Belgium, November 3, 2021 - Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.

"We are thrilled to welcome Gene as our new CFO," said Denis Bedoret, Ph.D., Chief Executive Officer of Imcyse. "Gene brings a deep knowledge and expertise of the financial sector, and I am confident that he will be an invaluable addition to our global executive management team as we work to pioneer the next generation of immunotherapeutics in autoimmune diseases."

Mr. Mack has over 25 years of experience in the life sciences sector, with particular focus on capital markets, business development and corporate finance. Mr. Mack joins Imcyse from OncoC4, a privately held biotechnology company that spun out of MSD's acquisition of OncoImmune. In addition to orchestrating the successful transaction between the two companies, he oversaw OncoC4's financial establishment. Before that, Mr. Mack was CFO for a number of development-stage and commercial-stage biopharmaceutical companies, raising over $150 million in IPO proceeds and other equity transactions in the past three years alone. With over $600 million in M&A and licensing transactions to go along with his capital markets expertise, Mr. Mack brings a proven track record of success in the biotechnology space. Prior to transitioning to an operational CFO seven years ago, Mr. Mack spent over fifteen years as a senior publishing analyst covering biotechnology and life sciences for a number of investment banks, including Gruntal & Co., Lazard and HSBC. Gene holds an MBA in Finance and a B.S. in Biochemistry, both from Fordham University.

"I am excited to join Imcyse during this meaningful stage of scientific and corporate growth," said Mr. Mack. "The Company's novel platform and clinical progress achieved to date uniquely positions Imcyse to deliver on near-term program milestones, and I look forward to working closely with Imcyse's exceptionally talented and experienced team to bring revolutionary potential treatment options to patients."

ABOUT IMCYSE
Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of chronic autoimmune diseases. The Company's unique platform allows the targeting of immune cells involved in the autoimmune cascade. This platform is based on the administration of Imotopes(TM), modified peptides that stimulate the generation of cytolytic CD4 T-cells that induce cell death specifically in disease related antigen presenting cells and autoantigen-specific lymphocytes. Imcyse's approach, helps to treat and prevent diseases which often have no therapeutic alternative and to potentially cure patients without impairing the immune defense. The Company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes(TM) for the treatment of several autoimmune diseases. Located in Liège, Belgium the company was founded as a spin-off of the Catholic University of Leuven.
www.imcyse.com

CONTACT:
Imcyse S.A.

Denis Bedoret
Chief Executive Officer
Mail: contact@imcyse.com

Investor Relations:
Stern Investor Relations

Jonathan Nugent
Mail: jonathan.nugent@sternir.com
Tel.: +1 212-698-8698

For Media Inquires:
MC Services AG

Anne Hennecke / Julia Bittner
Mail: imcyse@mc-services.eu
Tel.: +49 (0) 211-529-252-28


03.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting